Chronic Fatigue Syndrome A 2004 randomized trial demonstrated decreased fatigue severity and improved quality of life metrics in patients with chronic fatigue syndrome after 24 weeks of treatment at 2 grams daily [5][32]
Eli Lilly and Company Eli Lilly is gaining significant market share with Tirzepatide (Zepbound), a dual GLP-1 and GIP receptor agonist showing superior weight loss and metabolic benefits
Reassure: Help patients understand that this hair loss is usually transient and should improve as weight and nutritional status stabilises Nutrition guidance: Stress the importance of adequate protein intake and essential micronutrients (especially iron, zinc, B12, folate and vitamin D) during weight loss
#SouthPark #ParamountPlus | South Park
EXPERT FORMULATED: Formulated By GLP-1 Experts
Never Share a SOLIQUA 100/33 SoloStar Pen between Patients: Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed